Greenwich Lifesciences Inc (GLSI) — 13F Filings Explorer (Q2 2026)

GLSI ranks #5696 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

60 institutions disclose a position in GLSI, but none treat it as a major bet — even Gsa Capital Partners LLP, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

BlackRock has added to its GLSI position for two straight quarters, increasing it by $3.6M to reach $11.4M today.

Barclays PLC has trimmed its GLSI position for two straight quarters, cutting it by $184.8K while still holding $19.9K.

GLSI is down 1.9% today, but institutions show net buying of $4.1M this quarter — a divergence between today's price move and the underlying institutional flow.

GLSI reported a net loss of $19.4M in its latest fiscal year.

• Not yet profitable — net loss of $19.4M in the latest fiscal year
• Net income declined year over year, from -$17.4M to -$19.4M
• Operating cash flow was negative, using $9.9M in cash
• Current ratio of 1.06x — below the conventional 1.5x liquidity buffer
• Liabilities run 407.36x equity — a highly leveraged balance sheet worth noting